Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
214.53B
Market cap214.53B
Price-Earnings ratio
12.09
Price-Earnings ratio12.09
Dividend yield
2.39%
Dividend yield2.39%
Average volume
8.55M
Average volume8.55M
High today
$50.68
High today$50.68
Low today
$45.59
Low today$45.59
Open price
$47.40
Open price$47.40
Volume
11.61M
Volume11.61M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

MarketWatch 36m
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Shares of Novo Nordisk tumbled on Friday after the healthcare giant said that a drug it was developing to treat heart disease, kidney disease and inflammation f...

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
Benzinga 57m
Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients

Novo Nordisk A/S (NYSE:NVO) stock plunged on Friday after the company announced disappointing headline results from its ZEUS Phase 3 cardiovascular outcomes tri...

Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients
Simply Wall St 1h
Amgen Stock Leads 3 Cardiovascular Pharma Picks After Novo Nordisk Trial Miss

A failed late stage heart drug trial at Novo Nordisk, with shares in Copenhagen down 8.6% and U.S. ADRs down 9.8% in premarket trading, has pushed cardiovascula...

Amgen Stock Leads 3 Cardiovascular Pharma Picks After Novo Nordisk Trial Miss

Analyst ratings

57%

of 37 ratings
Buy
37.8%
Hold
56.8%
Sell
5.4%

More NVO News

TipRanks 1h
Novo Nordisk’s ZEUS Trial Finds No Cardiovascular Event Reduction With Ziltivekimab

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 2h
Novo Nordisk Stock Plunges 10% as Weight-Loss Drug Trial Disappoints

Shares of Novo Nordisk (NVO) are down 10% on July 31 after the European pharmaceutical giant reported disappointing results from its latest weight-loss drug tri...

The Wall Street Journal 2h
Novo Nordisk Shares Drop After Drug Candidate Fails in Cardiovascular Trial

Novo Nordisk plans to continue testing ziltivekimab in people with heart failure and in people who have suffered an acute heart attack. Florence Lo / Reuters N...

Novo Nordisk Shares Drop After Drug Candidate Fails in Cardiovascular Trial
TipRanks 3h
Novo Nordisk reports ziltivekimab did not yield MACE benefits in ZEUS study

Novo Nordisk (NVO) announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagement and inhibit...

Nasdaq 2d
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Key Points Amgen wants a slice of the weight loss drug market. Its candidate for capturing that market share might not be up to the task. Its competitors are...

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients
Simply Wall St 2d
Novo Nordisk Stock Looks Undervalued On Cash Flow And Earnings

Novo Nordisk stock is coming off a weak patch over the past three years, yet current valuation checks and an intrinsic value estimate suggest the market price m...

Novo Nordisk Stock Looks Undervalued On Cash Flow And Earnings
TipRanks 3d
Novo Nordisk’s ZEUS Trial Reaches Completion: What It Could Mean for NVO Investors

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.